Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery

NCT06959511 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Neoadjuvant Treatment
Thyroid Cancer

Interventions

DRUG: Zanzalintinib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]